Navigation Links
A&G Pharmaceutical Receives $870,000 Grant from Avon Foundation to Advance Innovative Blood Diagnostic Test for Early Detection of Breast Cancer
Date:12/14/2007

COLUMBIA, Md., Dec. 14 /PRNewswire/ -- A&G Pharmaceutical announced today that the Avon Foundation Breast Cancer Prevention Research Initiative has awarded A&G an $870,000 grant to conduct multicenter clinical studies focused on measuring levels of A&G's proprietary breast cancer biomarker, GP88, in blood and tissue samples from breast cancer patients. Results of the studies could provide the basis for developing a blood test that would enable early detection of breast cancer.

The award was one of 12 grants totaling more than $7 million awarded this year by the Avon Foundation as part of its Breast Cancer Prevention Research Initiative, and it is the first ever awarded by the foundation to a private company.

The GP88 blood diagnostic test is one of two breast cancer test kits in late-stage development by A&G. In addition to the blood test, A&G is developing a tissue biopsy test that would help pathologists and oncologists predict risk of recurrence in breast cancer patients. Both diagnostic tests are based on A&G's patented, proprietary GP88 growth factor, a protein found in circulating blood and tissue of breast cancer patients. Concurrently, A&G is developing a monoclonal antibody therapeutic that neutralizes the function of GP88 in breast cancer. The National Cancer Institute recently awarded A&G a $120,000 Phase I Small Business Innovation Research (SBIR) grant to support development of this new anti-GP88 therapeutic.

"Breast cancer is the most commonly diagnosed cancer in women-a projected 1.2 million new cases of breast cancer will be diagnosed this year-and early detection, when the disease is most treatable, continues to be a major worldwide challenge," said Carol Kurzig, Executive Director of the Avon Foundation. "We are very pleased to make this award to A&G Pharmaceutical, whose highly sensitive GP88 test has the potential to detect breast cancer cells at the earliest stage of the disease."

"We greatly appreciate Avon's
'/>"/>

SOURCE A&G Pharmaceutical
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
2. Skystar Bio-Pharmaceutical Announces Second Quarter 2007 Results
3. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
4. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
5. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
6. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
7. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
8. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
9. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
10. Heritage and Ipca Enter Into Strategic Alliance for Generic Pharmaceutical Products
11. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... (MIPT and Russian Quantum Center at Skolkovo) and ... and the Institute of Physics in Bratislava, Slovakia) ... of particles passing through an amplifier and, conversely, ... are provided in an article published in the ... , Quantum entangled particles are considered to be ...
(Date:7/23/2014)... July 23, 2014 Shimadzu Scientific ... amino acid analysis system developed jointly with Ajinomoto ... Station can analyze 38 amino acids in nine ... Station achieves high-speed analysis utilizing a fast application-specific ... provides accurate analytical results even under conditions with ...
(Date:7/23/2014)... StemGenex® , the leading resource for ... at improving the lives of patients dealing with degenerative ... disease. StemGenex believes that a commitment to the ... when providing care to patients with degenerative diseases. ... accessible to the millions of individuals currently living with ...
(Date:7/23/2014)... -- regulated information -- UCB today announced an important ... positive topline results from the latest Phase 3 ... to evaluate the efficacy and safety of ... compared to placebo, as adjunctive treatment in adult ... controlled despite treatment with one or two concomitant ...
Breaking Biology Technology:Scientists find way to maintain quantum entanglement in amplified signals 2Scientists find way to maintain quantum entanglement in amplified signals 3Scientists find way to maintain quantum entanglement in amplified signals 4Shimadzu's New UF-Amino Station Provides High-Speed, Multi-Component Analysis of Amino Acids in Food & Beverage and Pharmaceutical Testing 2StemGenex® Gives Hope to Parkinson’s Patients through New Stem Cell Clinical Study 2StemGenex® Gives Hope to Parkinson’s Patients through New Stem Cell Clinical Study 3Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 2Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 3Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 4Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 5Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 6Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 7
... a Madison-based company engaged in gene therapy and the study of ... new injection delivery method. , ,The company has been working to ... such as RNA for the study of gene function, and along ... developed a more rapid method of injection. , ,RNA interference ...
... Editor's note: This is the final in a three-part ... part of WTN Media's Boardroom Perspectives column, are written ... Candela Solutions, LLC . , ,According to the ... percent of frauds are detected by someone saying something ...
... my last article of the year, and I have talked less ... Year's resolution for this column is bring back more music (hopefully ... I simply have not gone to as many concerts this past ... to remedy!) , ,Looking over 2006, my focus has been more ...
Cached Biology Technology:Mirus Bio awarded patent on RNA delivery 2Mirus Bio awarded patent on RNA delivery 3I can tell you - you're my lawyer, right? 2I can tell you - you're my lawyer, right? 3I can tell you - you're my lawyer, right? 4I can tell you - you're my lawyer, right? 5I can tell you - you're my lawyer, right? 62006: A great biotech financing year, unless you were going public! 22006: A great biotech financing year, unless you were going public! 32006: A great biotech financing year, unless you were going public! 42006: A great biotech financing year, unless you were going public! 5
(Date:7/23/2014)... (PHILADELPHIA) The Worldwide Innovative Networking in personalized cancer ... Kimmel Cancer Center at Thomas Jefferson University ... the only member of this prestigious group in the ... the delivery of innovative personalized medicine to the patient ... patient advocacy. , "Our participation in the WIN consortium ...
(Date:7/23/2014)... clinical use of induced pluripotent stem cell (iPSC) ... hindered by the risk of dysregulated cell growth, ... use etoposide treatment to halt teratoma formation in ... acute myocardial infarction, is demonstrated in an article ... peer-reviewed journal from Mary Ann Liebert, Inc., publishers. ...
(Date:7/23/2014)... , July 23, 2014 ... its new report, GLOBAL MARKETS AND TECHNOLOGIES FOR ... technologies is expected to grow to nearly $154.4 billion ... (CAGR) of 10.1%. The image, flow, and level sensors ...      (Logo: http://photos.prnewswire.com/prnh/20140723/694805 ) , ...
Breaking Biology News(10 mins):New partnership brings more personalized cancer treatment to Philadelphia 2Global Market for Sensors to Reach Nearly $154.4 Billion in 2020; Image Sensors Moving at 11.7% 2Global Market for Sensors to Reach Nearly $154.4 Billion in 2020; Image Sensors Moving at 11.7% 3
... study was conducted by researchers from Scripps Research; the ... Taiwan University. It is being published today in the ... Chi-Huey Wong is currently the Ernest W. Hahn Chair ... and directs the Scripps Research lab heading the study. ...
... is your goal, you can't do better than to emulate ... and an unusual pitching stroke that allows the bug to ... is a marvel of engineering. , Z. Jane Wang, professor ... research on flying systems and fluid dynamics today (Feb. 19) ...
... mention the cleaning product industry, repeatedly warn of their ... is raising the intriguing idea that persistent bacterial and ... Robert W. and Vivian K. Cahill Professor in Cancer ... an essay in the Feb. 24 issue of the ...
Cached Biology News:Enzyme inhibitors block replication of SARS virus 2Scientist uses dragonflies to better understand flight 2Scientists look to the Bahamas as a model for coral reef conservation 2Scientists look to the Bahamas as a model for coral reef conservation 3
... The LCMS-2010EV is a fully flexible quadrupole ... conventional HPLC, high-speed HPLC, 1-D and 2-D ... scale separations. It incorporates a drying gas ... for high sensitivity, especially for low-to-medium polarity ...
Vapor phase risers are available in various heights to accomodate a variety of inventory solutions. Risers are used to creat a false bottom in which the tanks platform rests and Liquid nitrogen is s...
SP6 RNA Polymerase, 50 l, 20 U/l ,Cap Scribe Buffer, 100 l, 5x conc....
...
Biology Products: